A Phase 1/2a Study of BMS-986205 Administered in Combination With Nivolumab (Anti-PD-1 Monoclonal Antibody) and in Combination With Both Nivolumab and Ipilimumab (Anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors

Trial Profile

A Phase 1/2a Study of BMS-986205 Administered in Combination With Nivolumab (Anti-PD-1 Monoclonal Antibody) and in Combination With Both Nivolumab and Ipilimumab (Anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Oct 2017

At a glance

  • Drugs BMS 986205 (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 24 May 2017 Ipilimumab added to treatments, Planned number of patients changed from 252 to 907, Primary endpoints changed, Trial Focus chnaged from only Adverse events to Adverse events plus Theraprutic.
    • 24 May 2017 Planned End Date changed from 1 Oct 2019 to 28 Feb 2020.
    • 24 May 2017 Planned primary completion date changed from 1 Dec 2018 to 29 Apr 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top